These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23075237)

  • 1. Biomarkers for the diagnosis of new and recurrent prostate cancer.
    Sardana G; Diamandis EP
    Biomark Med; 2012 Oct; 6(5):587-96. PubMed ID: 23075237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.
    Saad F; Pantel K
    Future Oncol; 2012 Mar; 8(3):321-31. PubMed ID: 22409467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular diagnosis of prostate cancer: are we up to age?
    Bhavsar T; McCue P; Birbe R
    Semin Oncol; 2013 Jun; 40(3):259-75. PubMed ID: 23806492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for prostate cancer detection.
    Reed AB; Parekh DJ
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):103-14. PubMed ID: 20014890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary role of prostate cancer gene 3 in the management of prostate cancer.
    Roobol MJ
    Curr Opin Urol; 2011 May; 21(3):225-9. PubMed ID: 21301341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].
    Ohori M
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.
    Paris PL; Kobayashi Y; Zhao Q; Zeng W; Sridharan S; Fan T; Adler HL; Yera ER; Zarrabi MH; Zucker S; Simko J; Chen WT; Rosenberg J
    Cancer Lett; 2009 May; 277(2):164-73. PubMed ID: 19162393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCA3: from basic molecular science to the clinical lab.
    Day JR; Jost M; Reynolds MA; Groskopf J; Rittenhouse H
    Cancer Lett; 2011 Feb; 301(1):1-6. PubMed ID: 21093148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond PSA: are new prostate cancer biomarkers of potential value to New Zealand doctors?
    Ng L; Karunasinghe N; Benjamin CS; Ferguson LR
    N Z Med J; 2012 Apr; 125(1353):59-86. PubMed ID: 22522272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landmarks in prostate cancer diagnosis: the biomarkers.
    Artibani W
    BJU Int; 2012 Oct; 110 Suppl 1():8-13. PubMed ID: 23046035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).
    Kirby RS; Fitzpatrick JM; Irani J
    BJU Int; 2009 Feb; 103(4):441-5. PubMed ID: 19154510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
    Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
    Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage.
    Meid FH; Gygi CM; Leisinger HJ; Bosman FT; Benhattar J
    J Urol; 2001 May; 165(5):1802-5. PubMed ID: 11342979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Dueñas R
    Arch Esp Urol; 2013 May; 66(4):335-41. PubMed ID: 23676536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylated genes as potential biomarkers in prostate cancer.
    Phé V; Cussenot O; Rouprêt M
    BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ; Febbo PG
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
    Bickers B; Aukim-Hastie C
    Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization.
    Li X; Wong C; Mysel R; Slobodov G; Metwalli A; Kruska J; Manatt CS; Culkin DJ; Kropp BP; Lin HK
    Mol Cancer; 2005 Aug; 4(1):30. PubMed ID: 16086835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.